Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the biologics outsourcing market size evolved in recent years?

The biologics outsourcing market has experienced significant expansion in the past years. The market size, which was $20.06 billion in 2024, is projected to increase to $22.7 billion in 2025, with a compound annual growth rate (CAGR) of 13.2%. This surge during the historical period is due to factors such as rising R&D expenditures, regulatory obligations, the need for specialized knowledge, and globalization.

What are the predictions for the biologics outsourcing market size in the coming years?

Anticipations indicate a swift escalation in the biologics outsourcing market in the approaching years. With a compound annual growth rate (CAGR) of 13.4%, it is projected to reach $37.52 billion by 2029. Factors attributing to this growth during the predicted period could be recognized as the expansion in emerging markets, the rise of personalized medicine, strategic collaborations, and the expiration of biological drug patents. Noticeable trends likely to drive growth during this forecast period include tech advancements, the growing intricacies concerning outsourcing, the expansion of the biosimilars market, the integration of data analytics, and the strengthening of supply chain resilience.

Get your biologics outsourcing market report here!

https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

What key factors are fueling the growth of the biologics outsourcing market?

Increased instances of cancer are anticipated to boost the progression of the biologics outsourcing market. Cancer encompasses a vast range of diseases which can occur in almost any organ or tissue when unusual cells proliferate without control, surpass their normal boundaries, and spread or invade nearby body parts. Biologics outsourcing plays a crucial part in cancer instances by offering specialized knowledge, resources, and infrastructure for the creation, production, and clinical supply of biologic therapies. These include monoclonal antibodies, immunotherapies, and other targeted biologics employed for the diagnosis, treatment, and management of diverse types of cancer. For example, in January 2023, the National Center for Biotechnology Information, a US intergovernmental organization, reported 1,958,310 new cancer cases in the USA, with a projected figure of 609,820 cancer fatalities set to occur in 2023. Moreover, the yearly number of new cancer cases is predicted to escalate to 29.5 million, with cancer-related fatalities reaching 16.4 million by 2040. Therefore, this increasing number of cancer cases is fuelling the growth of the biologics outsourcing market.

How is the global biologics outsourcing market divided into key segments?

The biologics outsourcing market covered in this report is segmented –

1) By Product Type: Antibodies, Recombinant, Vaccines, Protein, Other Products

2) By Source: Human, Microbial, Other Source

3) By Application: Oncology, Cellular And Gene Therapy, Blood And Blood-Related Products Development, Vaccine Development, Stem Cell Research, Other Applications

4) By End User: Pharmaceutical Industries, Biotechnology Industries, Contract Development And Manufacturing Organization(CDMO)

Subsegments:

1) By Antibodies: Monoclonal Antibodies, Polyclonal Antibodies

2) By Recombinant: Recombinant Proteins, Recombinant DNA Products

3) By Vaccines: Therapeutic Vaccines, Preventive Vaccines

4) By Protein: Enzymes, Hormones, Cytokines

5) By Other Products: Gene Therapies, Cell Therapies, Biosimilars

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12573&type=smp

Who are the key firms paving the way for growth in the biologics outsourcing market?

Major companies operating in the biologics outsourcing market include AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim GmbH, Lonza Group Ag, Catalent Inc., Sartorius Stedim Biotech S.A., Charles River Laboratories International Inc., WuXi Biologics Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., CordenPharma GmbH, Ajinomoto Bio-Pharma Services, Syngene International Limited, Rentschler Biopharma SE, Albany Molecular Research Inc., KBI Biopharma Inc., Fujifilm Diosynth Biotechnologies Inc., Avid Bioservices Inc., BioVectra Inc., ProBioGen AG, ABL Inc., Vibalogics GmbH, JHL Biotech Inc., Goodwin Biotechnology Inc., Crown Bioscience Inc., Cytovance Biologics Inc., LakePharma Inc., AGC Biologics GmbH, Biomay AG, Polpharma Biologics S.A.

Which trends are expected to transform the biologics outsourcing market?

The rising trend of advancements in the sphere of biologics is making its mark in the biologics outsourcing market. Dominant corporations in this market are embracing novel technologies to maintain their standing. For instance, in February 2022, Abzena (a contract development and manufacturing organization from the US), Alira Health (a US-based healthcare company), and Oncodesign (a biopharmaceutical firm based in France) introduced DRIVE-Biologics. This is a consortium aimed at biologic drug discovery and development initiatives, offering integrated solutions along with expert services covering all aspects from biological discovery to clinical and commercial production. This alliance, unifying leadership in areas such as design and developability, evidencing concept in preclinical pharmacology and pharmaco-imaging, toxicology, and clinical design up to commercial manufacturing, intends to streamline communication and program outputs to mitigate risks associated with biologics development. The partners will also have the privilege to tap into the expertise available at every phase of drug discovery and development, including design, preclinical, clinical, and CMC (chemistry, manufacturing, and control).

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12573

What regions are contributing significantly to the growth of the biologics outsourcing market?

North America was the largest region in the biologics outsourcing market in 2024. The regions covered in the biologics outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Automotive Transmission Engineering Services Outsourcing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/automotive-transmission-engineering-services-outsourcing-global-market-report

IT Outsourcing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/it-outsourcing-global-market-report

Healthcare RCM Outsourcing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/healthcare-rcm-outsourcing-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: